Kathie-Ann Joseph

From Wikipedia, the free encyclopedia

Kathie-Ann P. Joseph, MD is the Director of Research in General Surgery and an Assistant Professor of Surgery at Columbia University College of Physicians & Surgeons. She is the first African-American woman appointed a faculty member in the Department of Surgery at Columbia (Fox 2005).

Dr. Joseph received her AB degree from Harvard University, and while there won the prestigious Hoopes Prize for Excellence in Undergraduate Research for her senior thesis in 1991 (Fox 2005). In 2004, she was selected as a Southwest Oncology Group Young Investigator and was the recipient of the 2004 American Association for Cancer Research Minority Scholar Award in Cancer Research (Fox 2005).

Dr. Joseph has been the recipient of a number of grants, including the Joanne Masin Breast Cancer Alliance Young Investigator Award from the National Institute of Health. She has received funding from Women-At-Risk of NewYork-Presbyterian Hospital and the American Cancer Society for her current research on ductal carcinoma in situ in African American women and RAGE, a receptor for advanced glycation endproducts in the treatment of breast cancer (Breast MD 2007).

In 2005, Dr. Joseph was selected by Crain's New York Business weekly as one of the top 40 under 40 young professionals who have made an impact on New York's business industry. It is particularly prestigious for Dr. Joseph, a breast surgeon, to be chosen since Crain's "40 Under 40" selects few professionals from outside of the business world (CS Joseph 2005). The same year, Dr. Joseph was also named one of the "Power Women of 2005" in New York Moves Magazine (CS Fellow 2005).

[edit] Selected Publications

Recurrent eosinophilic mastitis. Komenaka, I, Schnabel, F, Cohen, J, Saqi, AA, Mercado, C, Horowitz, E, Hamele-Bena, D, Joseph, KA. Am Surg. 69:620-623, 2003.
A forty year delayed locoregional recurrence of breast carcinoma following mastectomy. Joseph, KA, El-Tamer, M, Ditkoff, BA, Komenaka, I, Horowitz, L, Schnabel, F. Am Surg. 69(11):1015-6, 2003.
Indigent breast cancer patients among all racial and ethnic groups present with more advanced disease compared to nationally reported data. Naik A, Joseph, KA, Harris M, Davis C, Shapiro R, Hiotis K. Am J Surg. 186:400-403, 2003.
Soluble receptor for advanced glycation endproducts (sRAGE) effectively reduces tumor growth as a single agent and in combination with doxorubicin in a spontaneous mammary tumor model. Joseph, KA, Liu L, Qu W, Schnabel FR, Schmidt AM. J Surg Res. 114(2):251, Oct. 2003.